Genetic Subtype-Based International Prognostic Index Prognostic Model in Diffuse Large B-Cell Lymphoma

Abstract

Molecular subtyping in diffuse large B-cell lymphoma (DLBCL) leads to facilitating drug selection. However, an integrated prognostic model based on molecular subtyping and clinical features has not been well established. Here, we retrospectively performed whole genome sequencing, whole exome sequencing, and fluorescence in situ hybridization in newly diagnosed DLBCLs, established a simplified LymphType algorithm for classification evaluation, and proposed a new integrated prognostic stratification system, combined molecular subtypes and International Prognostic Index (IPI) scoring system in our in-house sequencing cohort (N = 100), and validated in three public cohorts (N = 1480). Compared with IPI scoring system and classification algorithm model alone, the discrimination ability of prognostic model based on the new integrated model showed best discrimination of overall survival with concordance index value (0.773 vs. 0.724 vs. 0.648). We subsequently established a four-category risk model defined for the integrated prognostic model as follows: low, low-intermediate, high-intermediate, and high risk, demonstrating stronger prognostic separation across all end points (all p < 0.001) in our in-house cohort and three validation cohorts. Collectively, the new feasible integrated prognostic stratification system contributes to accurate prognosis assessment in clinical routine and provides a new basis for the follow-up treatment.

Keywords

diffuse large B-cell lymphoma / defined genetic subtype / LymphType / International Prognostic Index / integrated prognostic model

References

[1] S. H. Swerdlow, E. Campo, S. A. Pileri, et al., “The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms,” Blood 127, no. 20 (2016): 2375-2390.

[2] R. Alaggio, C. Amador, I. Anagnostopoulos, et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms,” Leukemia 36, no. 7 (2022): 1720-1748.

[3] L. K. Hilton, D. W. Scott, and R. D. Morin, “Biological Heterogeneity in Diffuse Large B-cell Lymphoma,” Seminars in Hematology 60, no. 5 (2023): 267-276.

[4] A. Younes, J. Brody, C. Carpio, et al., “Safety and Activity of ibrutinib in Combination With nivolumab in Patients With Relapsed non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia: A Phase 1/2a Study,” The Lancet Haematology 6, no. 2 (2019): e67-e78.

[5] P. P. Xu, D. Fu, J. Y. Li, et al., “Anthracycline Dose Optimisation in Patients With Diffuse Large B-cell Lymphoma: A Multicentre, Phase 3, Randomised, Controlled Trial,” The Lancet Haematology 6, no. 6 (2019): e328-e337.

[6] A. P. Dabrowska-Iwanicka and G. S. Nowakowski, “DLBCL: Who is High Risk and How Should Treatment be Optimized?,” Blood 144, no. 25 (2023).

[7] International Non-Hodgkin's Lymphoma Prognostic Factors P. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. New England Journal of Medicine 1993; 329(14): 987-994.

[8] T. P. Miller, S. Dahlberg, J. R. Cassady, et al., “Chemotherapy Alone Compared With Chemotherapy plus Radiotherapy for Localized Intermediate- and High-grade Non-Hodgkin's Lymphoma,” New England Journal of Medicine 339, no. 1 (1998): 21-26.

[9] S. Merdan, K. Subramanian, T. Ayer, et al., “Gene Expression Profiling-based Risk Prediction and Profiles of Immune Infiltration in Diffuse Large B-cell Lymphoma,” Blood Cancer Journal 11, no. 1 (2021): 2.

[10] F. Frontzek, A. M. Staiger, R. Wullenkord, et al., “Molecular Profiling of EBV Associated Diffuse Large B-cell Lymphoma,” Leukemia 37, no. 3 (2023): 670-679.

[11] E. Bohers, P. J. Viailly, S. Becker, et al., “Non-invasive Monitoring of Diffuse Large B-cell Lymphoma by Cell-free DNA High-throughput Targeted Sequencing: Analysis of a Prospective Cohort,” Blood Cancer Journal 8, no. 8 (2018): 74.

[12] S. E. Lacy, S. L. Barrans, P. A. Beer, et al., “Targeted Sequencing in DLBCL, Molecular Subtypes, and Outcomes: A Haematological Malignancy Research Network Report,” Blood 135, no. 20 (2020): 1759-1771.

[13] A. Reddy, J. Zhang, N. S. Davis, et al., “Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma,” Cell 171, no. 2 (2017): 481-494.e15.

[14] R. D. Morin, M. Mendez-Lago, A. J. Mungall, et al., “Frequent Mutation of Histone-modifying Genes in non-Hodgkin Lymphoma,” Nature 476, no. 7360 (2011): 298-303.

[15] X. X. Cao, J. Li, H. Cai, W. Zhang, M. H. Duan, and D. B. Zhou, “Patients With Primary Breast and Primary Female Genital Tract Diffuse Large B Cell Lymphoma Have a High Frequency of MYD88 and CD79B Mutations,” Annal of Hematology 96, no. 11 (2017): 1867-1871.

[16] A. Tanabe, J. Ndzinu, and H. Sahara, “Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients,” International Journal of Molecular Sciences 25, no. 23 (2024): 12807.

[17] R. Schmitz, G. W. Wright, D. W. Huang, et al., “Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 378, no. 15 (2018): 1396-1407.

[18] B. Chapuy, C. Stewart, A. J. Dunford, et al., “Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated With Distinct Pathogenic Mechanisms and Outcomes,” Nature Medicine 24, no. 5 (2018): 679-690.

[19] G. W. Wright, D. W. Huang, J. D. Phelan, et al., “A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma With Therapeutic Implications,” Cancer Cell 37, no. 4 (2020): 551-568.e14.

[20] R. Shen, D. Fu, L. Dong, et al., “Simplified Algorithm for Genetic Subtyping in Diffuse Large B-cell Lymphoma,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 145.

[21] M. C. Zhang, S. Tian, D. Fu, et al., “Genetic Subtype-guided Immunochemotherapy in Diffuse Large B Cell Lymphoma: The Randomized GUIDANCE-01 Trial,” Cancer Cell 41, no. 10 (2023): 1705-1716.e5.

[22] M. S. Mendeville, J. Janssen, G. T. Los-de Vries, et al., “Integrating Genetic Subtypes With PET Scan Monitoring to Predict Outcome in Diffuse Large B-cell Lymphoma,” Nature Communications 16, no. 1 (2025): 109.

[23] C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al., “Confirmation of the Molecular Classification of Diffuse Large B-cell Lymphoma by Immunohistochemistry Using a Tissue Microarray,” Blood 103, no. 1 (2004): 275-282.

[24] L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, et al., “Signatures of Mutational Processes in human Cancer,” Nature 500, no. 7463 (2013): 415-421.

[25] L. Pedrosa, I. Fernandez-Miranda, D. Perez-Callejo, et al., “Proposal and Validation of a Method to Classify Genetic Subtypes of Diffuse Large B Cell Lymphoma,” Scientific Reports 11, no. 1 (2021): 1886.

[26] E. Le Goff, P. Blanc-Durand, L. Roulin, et al., “Baseline Circulating Tumour DNA and Total Metabolic Tumour Volume as Early Outcome Predictors in Aggressive Large B-cell Lymphoma. A Real-world 112-patient Cohort,” British Journal of Haematology 202, no. 1 (2023): 54-64.

[27] D. J. Landsburg, J. J. Morrissette, S. D. Nasta, et al., “TP53 mutations Predict for Poor Outcomes in Patients With Newly-diagnosed Aggressive B Cell Lymphomas in the Current Era,” Blood Advances 7, no. 23 (2023): 7243-7253.

[28] Y. Fang, M. C. Zhang, Y. He, et al., “Human Endogenous Retroviruses as Epigenetic Therapeutic Targets in TP53-mutated Diffuse Large B-cell Lymphoma,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 381.

[29] Z. Li, F. Yu, W. Ye, et al., “Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma,” Frontiers in Oncology 11 (2021): 746577.

[30] A. A. Alizadeh, M. B. Eisen, R. E. Davis, et al., “Distinct Types of Diffuse Large B-cell Lymphoma Identified by Gene Expression Profiling,” Nature 403, no. 6769 (2000): 503-511.

[31] A. Rosenwald, G. Wright, W. C. Chan, et al., “The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large-B-cell Lymphoma,” New England Journal of Medicine 346, no. 25 (2002): 1937-1947.

[32] T. Mishina, N. Oshima-Hasegawa, S. Tsukamoto, et al., “Genetic Subtype Classification Using a Simplified Algorithm and Mutational Characteristics of Diffuse Large B-cell Lymphoma in a Japanese Cohort,” British Journal of Haematology 195, no. 5 (2021): 731-742.

[33] W. H. Wilson, G. W. Wright, D. W. Huang, et al., “Effect of Ibrutinib With R-CHOP Chemotherapy in Genetic Subtypes of DLBCL,” Cancer Cell 39, no. 12 (2021): 1643-1653.e3.

[34] Y. Wang, Q. Shi, Z. Y. Shi, et al., “Biological Signatures of International Prognostic Index in Diffuse Large B-cell Lymphoma,” Blood Advances 8, no. 7 (2024): 1587-1599.

[35] K. Cibulskis, M. S. Lawrence, S. L. Carter, et al., “Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples,” Nature Biotechnology 31, no. 3 (2013): 213-219.

[36] K. Wang, M. Li, and H. Hakonarson, “ANNOVAR: Functional Annotation of Genetic Variants From High-throughput Sequencing Data,” Nucleic Acids Research 38, no. 16 (2010): e164.

[37] L. Raman, A. Dheedene, M. De Smet, J. Van Dorpe, and B. Menten, “WisecondorX: Improved Copy Number Detection for Routine Shallow Whole-genome Sequencing,” Nucleic Acids Research 47, no. 4 (2019): 1605-1614.

[38] C. Sha, S. Barrans, F. Cucco, et al., “Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy,” Journal of Clinical Oncology 37, no. 3 (2019): 202-212.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.